
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is a promising clinical-stage biotechnology company utilizing its proprietary Native Complex Platform to unlock the potential of GPCR therapies. Not only has the company received a significant upfront payment of $195M from its partnership with Novo Nordisk, but it is also making progress on multiple discovery-stage programs in various therapeutic areas. With a strong focus on endocrinology, immunology, and inflammation, as well as metabolic disease, Septerna has the potential to deliver innovative and potentially game-changing treatments to patients in need.
Bears say
Septerna is facing several risks and challenges, including potential delays in advancing their pipeline of product candidates, setbacks in clinical trials, and partnership risks, specifically with Novo Nordisk. Their valuation is based on a discounted cash flow model, with a price objective of $35 per share, reflecting a total firm value of approximately $1.57 billion. However, there is a potential for lower-than-expected market penetration rates and long-term dilution risk, which could impact the achievement of this price target. Septerna's success may also hinge on securing approval for key candidates and generating significant sales in the highly competitive and lucrative GPCR therapy market.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares